Sogarjo
Integrated oncology institution

Built for the gap.

2 platforms making complex bioinformatics interpretable for everyone. From raw RNA-seq to clinical report — end to end. Molecular evidence that clinicians can actually read and act on. Building the infrastructure layer that oncology needs now.

Sogarjo builds vertically integrated cancer infrastructure from the data layer upward: clinical genomics software, molecular diagnostics, purpose-built instruments, therapeutic discovery, and research systems.

Active products Five-layer vision

Cancer infrastructure cannot be imported into every clinical reality.

Sogarjo exists to build that infrastructure layer by layer, from the data up—so underserved institutions can generate, interpret, and act on their own molecular evidence.

Layer 1 — Active software

The first layer is already being built.

Active software creates the molecular analysis surface that later diagnostics, instruments, and research programs feed back into.

HemaLignC

RNA-seq classification and reporting for hematologic malignancies.

Fusion detection, molecular subtype classification, lineage prediction, variant review, and automated clinical-style reporting.

RNA-seq Fusion detection Lineage prediction Automated reports
View Platform Demo →
RUO — Research Use Only
1

Sample input

Sequencing files, metadata, panels, and reference assets for reproducible pipeline execution.

2

Analysis

Fusion, variant, expression, quantification, QC, and review workflows for hematologic malignancy cohorts.

3

Prediction

Lineage and subtype classifiers applied to expression-derived and variant-supported evidence.

4

Reporting

Structured outputs for interpretation, review, and clinical-style documentation.

HeMaRD

DNA-seq MRD tracking and clonal evolution for acute leukemias.

Ultra-low VAF detection, longitudinal MRD tracking, CNV/SV integration, clonal evolution, and ELN 2022 risk classification.

Mutect2 VarDict PyClone-VI ELN 2022
In development
RUO — Research Use Only
1

MRD detection

Mutect2, HaplotypeCaller, and VarDict with force-calling of diagnostic index variants across timepoints.

2

Clonal evolution

VAF trajectories with PyClone-VI-style clone clustering, clonal sweeps, and subclonal MRD patterns.

3

CNV and SV context

Copy-number and structural variant calls integrated with SNV/indel evidence across diagnosis, response, and relapse.

4

Risk dashboard

ELN 2022 AML and B-ALL adverse-risk classification with per-timepoint MRD status reports.

The five-layer build

Software is the first layer, not the final ambition.

Each layer creates data, standards, tools, and capacity that make the next layer possible.

L1
Active

Software

HemaLignC and HeMaRD: RNA-seq classification, MRD tracking, reporting, and reproducible pipeline infrastructure.

L2
Future

Diagnostics

Validated molecular panels, affordable reagent workflows, and assay standardization for institutions without access to commercial solutions.

L3
Future

Instruments

Purpose-built cancer detection hardware designed for the actual constraints of underserved hospitals.

L4
Future

Drug Development

Translational programs using cohort data, molecular classifiers, and MRD tracking to identify therapeutic targets in underrepresented cancer biology.

L5
Future

Research Infrastructure

Independent labs, fellowships, and a scientific network that feeds discovery back into every layer.

Institutional divisions

One institution, multiple build surfaces.

LS Active

Sogarjo Life Sciences

HemaLignC and HeMaRD: clinical genomics software for classification, MRD tracking, and reporting.

DX Future

Sogarjo Diagnostics

Molecular panels, affordable reagent workflows, and assay standards for resource-constrained oncology institutions.

HW Future

Sogarjo Instruments

Purpose-built cancer detection hardware engineered for real hospital constraints.

TX Future

Sogarjo Therapeutics

Drug development from cohort data, molecular classifiers, and MRD-linked disease biology.

AI Future

Sogarjo Intelligence

AI decision support, biomedical models, and scientific reasoning systems built on cohort evidence.

RS Future

Sogarjo Research

Independent labs, fellows, and a discovery network that feeds science back into every division.

Every layer we build is infrastructure someone else doesn’t have to build from scratch.

Open to scientific collaborators, clinical partners, and institutions building serious oncology capacity.

Collaborate